Frank Vinluan is a Senior Biopharma Reporter for MedCity News. With a focus on the biopharmaceutical industry, Frank covers topics such as drug approvals, mergers and acquisitions, clinical trial data, and advancements in gene therapy and cell therapy. His articles provide insights into the latest developments and trends in the biopharma sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Frank Vinluan's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions, drug development, FDA approvals, and biotech. He frequently cites data in his articles, indicating a reliance on factual evidence.
Given his focus on M&A deals and drug developments within the healthcare sector, Frank may be interested in receiving pitches related to exclusive insights from industry experts or company executives involved in these transactions or new developments. Pitches emphasizing unique data-driven analyses or perspectives from key opinion leaders could also resonate well with him.
As there is no specific geographic focus mentioned for Frank's reporting, relevant news or expert analysis from any location within the global pharmaceutical and biotech industries would likely be of interest to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Frank Vinluan
The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the product comes two years after it won its first regulatory approvals in Europe.
By: Frank Vinluan
Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF.
By: Frank Vinluan
Halozyme's offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
By: Frank Vinluan
Vesalius Therapeutics' AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson's disease target is now headed to GSK, which has licensed global rights.
By: Frank Vinluan
Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen.
By: Frank Vinluan
Approval of Syndax's Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin.
By: Frank Vinluan
Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant's top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.
By: Frank Vinluan
Valora Therapeutics' antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup's science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.
By: Frank Vinluan
Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals' Revuforj, which won FDA approval last week.
By: Frank Vinluan
A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. But Neurogene is able to avoid a lengthy clinical trial pause largely because of its participation in an FDA pilot program intended to speed up the development of therapies for rare diseases.
(833) 317-6278 
